US combi product dispute guidance from FDA
This article was originally published in Clinica
The US FDA has issued a guidance on filing dispute resolution requests when the agency fails to review and act on a combination product submission within the statutory time frame. In addition to noting who to contact and what to include in the request, the guidance explains when a formal request is appropriate and when it is not.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.